Merck’s Novel HIV Drug Isentress Granted Six-Month FDA Review
This article was originally published in The Pink Sheet Daily
Executive Summary
First-in-class integrase inhibitor could see a mid-October approval.
You may also be interested in...
Merck Vaccine Unit Tops $1 Billion In Second Quarter Sales On Strength Of New Products
Gardasil sales, however, were down sequentially compared to the first quarter.
Merck Vaccine Unit Tops $1 Billion In Second Quarter Sales On Strength Of New Products
Gardasil sales, however, were down sequentially compared to the first quarter.
Gilead’s Elvitegravir Phase III Could Face Challenges With Novel HIV Comparator
Integrase inhibitor will likely need to be compared to active control such as investigational maraviroc or raltegravir in Phase III, firm reports.